Treatment with un-licensed medicine

6 trials

Sponsors

Yamamoto Kei, Yamaoto Kei, Maruyama Haruhiko

Conditions

ChagasCongenital toxoplasmosisDisseminated toxoplasmosis and toxoplasma encephalitisFasciolosisFetal toxoplasmosismalaria

Phase 3

Treatment of congenital toxoplasmosis with pyrimethamine/sulfadiazine

RecruitingJPRN-jRCTs071180093

Maruyama HaruhikoCongenital toxoplasmosis

Start: 2020-02-03Target: 35Updated: 2025-11-17

Treatment of fetal toxoplasmosis with pyrimethamine/sulfadiazine

RecruitingJPRN-jRCTs071180094

Maruyama HaruhikoFetal toxoplasmosis

Start: 2019-06-18Target: 35Updated: 2025-11-17

Treatment of disseminated toxoplasmosis/toxoplasma encephalitis with pyrimethamine/sulfadiazine

RecruitingJPRN-jRCTs071180095

Maruyama HaruhikoDisseminated toxoplasmosis and toxoplasma encephalitis

Start: 2020-03-18Target: 35Updated: 2025-12-08

Fasciolosis treatment with Egaten

RecruitingJPRN-jRCTs071190020

Yamamoto KeiFasciolosis

Start: 2019-08-30Target: 75Updated: 2026-09-14

Treatment of severe malaria with intravenous quinine (Injectable artesunate for malaria)

RecruitingJPRN-jRCTs031240737

Yamamoto Keimalaria

Start: 2025-12-16Target: 40Updated: 2026-06-29

Specific Clinical Study of Benznidazole and Nifurtimox for Chagas Disease

RecruitingJPRN-jRCTs031250123

Yamaoto KeiChagas

Start: 2025-10-29Target: 45Updated: 2026-06-29